AIMS: The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in patients with congestive heart failure. METHODS: Levosimendan was administered as a continuous intravenous infusion for 7 days. Twelve subjects received the drug at an infusion rate of 0.05 micro g kg(-1) min(-1) and 12 at a rate 0.1 micro g kg(-1) min(-1). RESULTS: Steady state concentrations of levosimendan were achieved within 4 h. Peak concentrations of the metabolites occurred after termination of the infusion. The mean (+/- SD) half-life of the active metabolite OR-1896 was 81 +/- 37 h after the lower dose and 81 +/- 28 h after the higher dose (P = 0.992, 95% confidence interval on the difference -27.5, 27.7). CONCLUSIONS: The metabolites of levosimendan, OR-1855 and OR-1896, were formed and eliminated slowly, their peak concentrations occurring after termination of the 7-day infusion of the drug.
AIMS: The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in patients with congestive heart failure. METHODS:Levosimendan was administered as a continuous intravenous infusion for 7 days. Twelve subjects received the drug at an infusion rate of 0.05 micro g kg(-1) min(-1) and 12 at a rate 0.1 micro g kg(-1) min(-1). RESULTS: Steady state concentrations of levosimendan were achieved within 4 h. Peak concentrations of the metabolites occurred after termination of the infusion. The mean (+/- SD) half-life of the active metabolite OR-1896 was 81 +/- 37 h after the lower dose and 81 +/- 28 h after the higher dose (P = 0.992, 95% confidence interval on the difference -27.5, 27.7). CONCLUSIONS: The metabolites of levosimendan, OR-1855 and OR-1896, were formed and eliminated slowly, their peak concentrations occurring after termination of the 7-day infusion of the drug.
Authors: E P Sandell; M Hayha; S Antila; P Heikkinen; P Ottoila; L A Lehtonen; P J Pentikainen Journal: J Cardiovasc Pharmacol Date: 1995 Impact factor: 3.105
Authors: F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen Journal: Lancet Date: 2002-07-20 Impact factor: 79.321
Authors: Jaakko Puttonen; Sampo Kantele; Matti Kivikko; Sari Häkkinen; Veli-Pekka Harjola; Petri Koskinen; Pertti J Pentikäinen Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447
Authors: Patrick Scheiermann; Devan Ahluwalia; Sandra Hoegl; Andrea Dolfen; Marc Revermann; Bernhard Zwissler; Heiko Muhl; Kim A Boost; Christian Hofstetter Journal: Intensive Care Med Date: 2009-04-15 Impact factor: 17.440
Authors: Christoph Maack; Thomas Eschenhagen; Nazha Hamdani; Frank R Heinzel; Alexander R Lyon; Dietmar J Manstein; Joseph Metzger; Zoltán Papp; Carlo G Tocchetti; M Birhan Yilmaz; Stefan D Anker; Jean-Luc Balligand; Johann Bauersachs; Dirk Brutsaert; Lucie Carrier; Stefan Chlopicki; John G Cleland; Rudolf A de Boer; Alexander Dietl; Rodolphe Fischmeister; Veli-Pekka Harjola; Stephane Heymans; Denise Hilfiker-Kleiner; Johannes Holzmeister; Gilles de Keulenaer; Giuseppe Limongelli; Wolfgang A Linke; Lars H Lund; Josep Masip; Marco Metra; Christian Mueller; Burkert Pieske; Piotr Ponikowski; Arsen Ristić; Frank Ruschitzka; Petar M Seferović; Hadi Skouri; Wolfram H Zimmermann; Alexandre Mebazaa Journal: Eur Heart J Date: 2019-11-21 Impact factor: 29.983